Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis
Cell Biology and Toxicology · 2025
DOI: 10.1007/s10565-025-10115-6 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cell Biology and Toxicology, 2025. Verfasst von Xiaojuan Su und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics/Key Laboratory of Birth Defects and Related Diseases of Women and Children (Ministry of Education)/NHC Key Laboratory of Chr…. Hauptthemen laut MEDLINE: Inflammation, Telomere, Telomere Homeostasis. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Grant from the Science and Technology Bureau of Sichuan Province.
Abstract (Originalsprache)
BACKGROUND: TA-65®, a telomerase-activating compound derived from Astragalus membranaceus, has garnered interest for its potential to modulate cellular aging. However, its mechanistic efficacy and long-term toxicological profile remain inadequately synthesized. METHODS: This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65's effects on telomere dynamics, functional aging indices, and safety outcomes. Primary outcomes included leukocyte telomere length (LTL) measured by Southern blot or qPCR/or flow-FISH; secondary outcomes encompassed frailty metrics (SPPB, grip strength, 6MWT), inflammatory markers (hs-CRP, IL-6), and adverse events (CTCAE v5.0). Statistical synthesis employed random-effects models (RevMan 5.3), subgroup analyses, and GRADE evidence grading. RESULTS: TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p 60 years (SMD = 0.63 vs. 0.36; p = 0.03). Industry-funded trials reported inflated efficacy (SMD = 0.63 vs. 0.40; p = 0.03). Critically, telomere elongation did not translate to functional improvements in frailty (SMD = 0.09, p = 0.15) or inflammation (CRP/IL-6 SMD = - 0.11, p = 0.07), revealing a telomere-function disconnect. Safety analysis (n = 487) identified mild gastrointestinal toxicity (12.4% incidence; nausea: 7.1%, abdominal discomfort: 5.3%) but no severe adverse events (e.g., oncogenesis) over 12 months. Dose-response relationships (10-50 mg/day) and measurement-method variations were non-significant (p > 0.05). CONCLUSIONS: While TA-65 demonstrates telomerase-activating efficacy, particularly in older adults, its failure to improve functional aging metrics underscores limitations of unimodal biomarker targeting. The absence of dose-dependent toxicity or short-term oncogenic risk is notable, yet long-term carcinogenic potential remains unaddressed. Rigorous, independent trials must evaluate TA-65's chronic toxicity, telomere-independent mechanisms, and utility within multidimensional aging frameworks. Clinical application may consider older adults with immunosenescence, incorporating safety surveillance for gastrointestinal and oncological endpoints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics/Key Laboratory of Birth Defects and Related Diseases of Women and Children (Ministry of Education)/NHC Key Laboratory of Chronobiology, West China Second University Hospital, Sichuan University,…
- School of Clinical Medicine & The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China.
ORCID-Profile: Yi Qu
Förderung
- National Natural Science Foundation of China
- Grant from the Science and Technology Bureau of Sichuan Province
Zitieren
APA
Su, X., Wang, C., Gou, Z., & Qu, Y. (2025). Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis. Cell Biology and Toxicology. https://doi.org/10.1007/s10565-025-10115-6
Vancouver
Su X, Wang C, Gou Z, Qu Y. Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis. Cell Biology and Toxicology. 2025. doi:10.1007/s10565-025-10115-6
BibTeX
@article{Su2025,
author = {Su, Xiaojuan and Wang, Cheng and Gou, Zhixian and Qu, Yi},
title = {Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis},
journal = {Cell Biology and Toxicology},
year = {2025},
doi = {10.1007/s10565-025-10115-6}
}
EUVIMED